Literature DB >> 18645040

Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies.

Penny Titman1, Elizabeth Pink, Emily Skucek, Katherine O'Hanlon, Tim J Cole, Jane Gaspar, Jinhua Xu-Bayford, Alison Jones, Adrian J Thrasher, E Graham Davies, Paul A Veys, H Bobby Gaspar.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is a highly successful treatment for severe congenital immunodeficiencies. However, some studies have suggested that children may experience cognitive difficulties after HSCT. This large-scale study assessed cognitive and behavioral function for the cohort of children treated by HSCT at one center between 1979 and 2003 to determine the frequency and severity of problems and to identify risk factors. A total of 105 patients were assessed on standardized measures of cognitive and emotional and behavioral function together with a control group of unaffected siblings. The average IQ for the cohort was 85 (95% confidence interval, 81-90), significantly lower than both the population average of 100 (P < .001) and unaffected siblings. Multivariate analysis indicated that the underlying genetic defect, diagnosis of adenosine deaminase-deficient severe combined immunodeficiency, and consanguinity were associated with worse outcome but that age at transplantation and chemotherapy conditioning were not. Children treated by HSCT for severe immunodeficiency have an increased risk of long-term cognitive difficulties and associated emotional and behavioral difficulties. The specific genetic diagnosis, consanguinity, and severe clinical course are associated with poor outcome. Long-term follow-up of these patients should include screening to identify and manage these problems more effectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645040     DOI: 10.1182/blood-2008-04-151332

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

Review 2.  How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).

Authors:  Donald B Kohn; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2017-02-14       Impact factor: 8.317

3.  A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).

Authors:  Kee Chan; Joie Davis; Sung-Yun Pai; Francisco A Bonilla; Jennifer M Puck; Michael Apkon
Journal:  Mol Genet Metab       Date:  2011-07-12       Impact factor: 4.797

4.  Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency.

Authors:  Robert Sokolic; Irina Maric; Chimene Kesserwan; Elizabeth Garabedian; I Celine Hanson; Margaret Dodds; Rebecca Buckley; Andrew C Issekutz; Naynesh Kamani; Kit Shaw; Ben Tan; Pawan Bali; Michael S Hershfield; Donald B Kohn; Alan S Wayne; Fabio Candotti
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

Review 5.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Authors:  Jennifer Heimall; Jennifer Puck; Rebecca Buckley; Thomas A Fleisher; Andrew R Gennery; Benedicte Neven; Mary Slatter; Elie Haddad; Luigi D Notarangelo; K Scott Baker; Andrew C Dietz; Christine Duncan; Michael A Pulsipher; Mort J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-06       Impact factor: 5.742

6.  Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.

Authors:  Justin T Wahlstrom; Christopher C Dvorak; Morton J Cowan
Journal:  Curr Pediatr Rep       Date:  2015-03-01

Review 7.  Long term outcomes of severe combined immunodeficiency: therapy implications.

Authors:  Jennifer Heimall; Morton J Cowan
Journal:  Expert Rev Clin Immunol       Date:  2017-09-23       Impact factor: 4.473

Review 8.  Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.

Authors:  William T Shearer; Thomas A Fleisher; Rebecca H Buckley; Zuhair Ballas; Mark Ballow; R Michael Blaese; Francisco A Bonilla; Mary Ellen Conley; Charlotte Cunningham-Rundles; Alexandra H Filipovich; Ramsay Fuleihan; Erwin W Gelfand; Vivian Hernandez-Trujillo; Steven M Holland; Richard Hong; Howard M Lederman; Harry L Malech; Stephen Miles; Luigi D Notarangelo; Hans D Ochs; Jordan S Orange; Jennifer M Puck; John M Routes; E Richard Stiehm; Kathleen Sullivan; Troy Torgerson; Jerry Winkelstein
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

9.  Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Jennifer M Puck; Rebecca H Buckley; Fabio Candotti; Mary Ellen Conley; Thomas A Fleisher; H Bobby Gaspar; Donald B Kohn; Hans D Ochs; Richard J O'Reilly; J Douglas Rizzo; Chaim M Roifman; Trudy N Small; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

10.  Neuroprotective effects of adenosine deaminase in the striatum.

Authors:  Risa Tamura; Hiroyuki Ohta; Yasushi Satoh; Shigeaki Nonoyama; Yasuhiro Nishida; Masashi Nibuya
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.